Professor Will Irving

Professor Will Irving

Queens Medical Centre Campus, Derby Road, Nottingham, NG7 2UH

+44 115 823 0752 View full bio
Professor of Virology

Clinical virology, especially in relation to viral hepatitis and the human herpes viruses. This encompasses diagnosis, management and pathogenesis of disease.

Studies
Title Start Date Status
Trent Study of patients with hepatitis C virus infection (HCV Trent Study) 1st January 2014 Active
Evaluation of interventions designed to increase diagnosis and treatment of patients with hepatitis 1st August 2014 Active
Trent Cohort study of patients infected with hepatitis C virus (Trent Cohort) 1st September 2010 Ended
Evaluation of antibodies to tumor associated antigens as a diagnostic test for hepatocellular carcin 10th August 2015 In Recruitment
Host and viral factors associated with outcomes of infection with hepatitis C virus (HCV Research UK 1st March 2012 In Recruitment
Generation of broadly neutralizing HCV-specific human monoclonal (Immune Study) 1st December 2009 Active
Grants
Title Amount
The Trent HCV Cohort study £400,000
Establishment of a resource for Long-Term study of hepatitis C Virus infection in the UK - HCV Resea £1,920,000
Validation of the Genedrive for HCV RNA testing £53,576.00
Stratified Medicine to optimise Treatment for HCV infection £5,200,000
Evaluation of Interventions designed to increase diagnosis and treatment of patients with HCV infect £1,112,000
Real world outcomes of treatment of HCV-infected patients based on the use of sofosbuvir £116,000
Publications
Title
Next Generation Sequencing and in Vitro Characterization Reveal Population Bottlenecks and Fixation
Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombo
Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B acro
Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected p
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cir
Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and
Development of a high-throughput pyrosequencing assay for monitoring temporal evolution and resistan
Antiviral treatment discontinuation among hepatitis C-infected individuals with thrombocytopenia
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis
SOX9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosi
Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus inf
Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection
Treatment of metastatic spinal lesions with a navigational bipolar radiofrequency ablation device: a
Clinical Care Pathways for Patients With Hepatitis C: Reducing Critical Barriers to Effective Treatm
Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank
Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct
Virology Question and Answer Scheme (VIROQAS) Hepatitis C virus infection
Serum Autoantibody Measurement for the Detection of Hepatocellular Carcinoma
In silico and in vitro interrogation of a widely used HEV RT-qPCR assay for detection of the species
Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected p
Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and
IFN-lambda 3, not IFN-lambda 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation
Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study
Using Surveillance Data to Determine Treatment Rates and Outcomes for Patients With Chronic Hepatiti
MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis
Reply to: “Reply to: ‘Response to DAA therapy in the NHS England Early Access Programme for rare HCV
Development and clinical validation of the Genedrive point-of-care test for qualitative detection of
Equilibrative nucleoside transporter 1 (ent1) expression is highly variable in primary human hepatoc
Hepatitis E: An emerging infection in high income countries
The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and adv
Understanding hepatitis C intervention success-Qualitative findings from the HepCATT study
Testing for hepatitis C virus infection in UK prisons: What actually happens?
Prevalence and risk factors for hepatitis C virus infection in Kech District, Balochistan, Pakistan:
Predictors of hepatitis C treatment response: what’s new?
Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease
Epidemiology and natural history of hepatitis C virus infection among children and young people
HCV Research UK: A UK national resource to support research into HCV infection
Use of short tandem repeat fingerprinting to validate sample origins in hepatitis C virus molecular
Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease pheno
Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK
Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral t
Autoantibodies in chronic hepatitis C virus infection and their association with disease profile
Pretreatment Lesions on Magnetic Resonance Imaging in Patients With Hepatitis C Virus Infection Diag
Become a Volunteer

Click here to find out how you can participate in our clinical trials
Patient & Public Involvement

Find out how you can help the Nottingham BRC to shape our research trials